Skip to main content
. 2000 Jun;68(6):3403–3411. doi: 10.1128/iai.68.6.3403-3411.2000

TABLE 1.

Specific elimination of P. yoelii-infected hepatocytes by restimulated spleen cells from mice immunized with MAP4(PyCSP57–70) in Lipofectin

No. of expt and condition Immunogen No. of spleen cells Spleen cell stimulant No. of schizonts/well (mean ± SD) % Inhibition
Expt 1
 BALB/c hepatocytes with BALB/c effector cells Lipofectin 1 × 106 MAP4(PyCSP57–70) 96, 108, 90 (98 ± 9)
Lipofectin 1 × 106 PfSSP2-15 113, 117, 91 (107 ± 14)
MAP4(PyCSP57–70) 1 × 106 MAP4(PyCSP57–70) 24, 21, 17 (21 ± 4) 79
MAP4(PyCSP57–70) 1 × 106 PfSSP2-15 87, 99, 88 (91 ± 7) 15
Expt 2
 BALB/c hepatocytes with BALB/c effector cells Lipofectin 1 × 106 MAP4(PyCSP57–70) 66, 71, 76 (71 ± 4)
Lipofectin 5 × 105 MAP4(PyCSP57–70) 59, 57, 73 (63 ± 7)
MAP4(PyCSP57–70) 1 × 106 MAP4(PyCSP57–70) 29, 21, 36 (28 ± 6) 60
MAP4(PyCSP57–70) 5 × 105 MAP4(PyCSP57–70) 42, 29, 27 (32 ± 6) 49
MAP4(PyCSP57–70) 2.5 × 105 MAP4(PyCSP57–70) 61, 62, 60 (61 ± 0.8) 3
MAP4(PyCSP57–70) 1 × 105 MAP4(PyCSP57–70) 74, 70, 73 (72 ± 1.6)
  CD8+ depletion MAP4(PyCSP57–70) 1 × 106 MAP4(PyCSP57–70) 60, 59, 70 (63 ± 5) 11
MAP4(PyCSP57–70) 5 × 105 MAP4(PyCSP57–70) 63, 56, 66 (61 ± 4) 3
  5 μM 1400W (iNOS inhibitor) MAP4(PyCSP57–70) 1 × 106 MAP4(PyCSP57–70) 63, 83, 66 (70 ± 9) 1
 C57BL/6 hepatocytes with BALB/c effector cells Lipofectin 1 × 106 MAP4(PyCSP57–70) 156, 152, 137 (148 ± 8)
Lipofectin 5 × 105 MAP4(PyCSP57–70) 200, 170, 183 (177 ± 6)
MAP4(PyCSP57–70) 1 × 106 MAP4(PyCSP57–70) 120, 176, 145 (147 ± 23) 1
MAP4(PyCSP57–70) 5 × 105 MAP4(PyCSP57–70) 147, 169, 198 (171 ± 20) 3
MAP4(PyCSP57–70) 2.5 × 105 MAP4(PyCSP57–70) 135, 154, 159 (150 ± 3) 15
MAP4(PyCSP57–70) 1 × 105 MAP4(PyCSP57–70) 160, 159, 142 (156 ± 4) 11
  CD8+ depletion MAP4(PyCSP57–70) 1 × 106 MAP4(PyCSP57–70) 165, 149, 161 (158 ± 7) 0
MAP4(PyCSP57–70) 5 × 105 MAP4(PyCSP57–70) 174, 148, 156 × (161 ± 13) 12